These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 35835062)
41. Follow-up and treatment of adults with cystinosis in the Netherlands. Geelen JM; Monnens LA; Levtchenko EN Nephrol Dial Transplant; 2002 Oct; 17(10):1766-70. PubMed ID: 12270982 [TBL] [Abstract][Full Text] [Related]
42. Cysteamine therapy for children with nephropathic cystinosis. Gahl WA; Reed GF; Thoene JG; Schulman JD; Rizzo WB; Jonas AJ; Denman DW; Schlesselman JJ; Corden BJ; Schneider JA N Engl J Med; 1987 Apr; 316(16):971-7. PubMed ID: 3550461 [TBL] [Abstract][Full Text] [Related]
43. A systematic literature review of cysteamine bitartrate in the treatment of nephropathic cystinosis. Medic G; van der Weijden M; Karabis A; Hemels M Curr Med Res Opin; 2017 Nov; 33(11):2065-2076. PubMed ID: 28692321 [TBL] [Abstract][Full Text] [Related]
44. Nephropathic cystinosis: effect of long-term cysteamine therapy. Proesmans W; Baten E; Hoogmartens J; Bruyneel P Clin Nephrol; 1987 Jun; 27(6):309-12. PubMed ID: 3608256 [TBL] [Abstract][Full Text] [Related]
45. Cysteamine (Cystagon®) adherence in patients with cystinosis in Spain: successful in children and a challenge in adolescents and adults. Ariceta G; Lara E; Camacho JA; Oppenheimer F; Vara J; Santos F; Muñoz MA; Cantarell C; Gil Calvo M; Romero R; Valenciano B; García-Nieto V; Sanahuja MJ; Crespo J; Justa ML; Urisarri A; Bedoya R; Bueno A; Daza A; Bravo J; Llamas F; Jiménez Del Cerro LA Nephrol Dial Transplant; 2015 Mar; 30(3):475-80. PubMed ID: 25348508 [TBL] [Abstract][Full Text] [Related]
46. Long-term clinical benefits of delayed-release cysteamine bitartrate capsules in patients with nephropathic cystinosis (response to "A comparison of immediate release and delayed release cysteamine in 17 patients with nephropathic cystinosis"). Langman CB Orphanet J Rare Dis; 2023 Jun; 18(1):162. PubMed ID: 37353838 [TBL] [Abstract][Full Text] [Related]
47. Plasma chitotriosidase enzyme activity as a novel therapeutic monitor for cysteamine treatment in nephropathic cystinosis: A retrospective validation study. Veys K; Elmonem MA; van den Heuvel L; Gahl WA; Levtchenko E Mol Genet Metab; 2024 May; 142(1):108454. PubMed ID: 38603816 [TBL] [Abstract][Full Text] [Related]
49. Long-term outcome of nephropathic cystinosis: a 20-year single-center experience. Greco M; Brugnara M; Zaffanello M; Taranta A; Pastore A; Emma F Pediatr Nephrol; 2010 Dec; 25(12):2459-67. PubMed ID: 20803298 [TBL] [Abstract][Full Text] [Related]
50. Predicted reciprocal serum creatinine at age 10 years as a measure of renal function in children with nephropathic cystinosis treated with oral cysteamine. Gahl WA; Schneider JA; Schulman JD; Thoene JG; Reed GF Pediatr Nephrol; 1990 Mar; 4(2):129-35. PubMed ID: 2397178 [TBL] [Abstract][Full Text] [Related]
51. Cystinosin-deficient rats recapitulate the phenotype of nephropathic cystinosis. Hollywood JA; Kallingappa PK; Cheung PY; Martis RM; Sreebhavan S; 'Atiola RD; Chatterjee A; Buckels EJ; Matthews BG; Lewis PM; Davidson AJ Am J Physiol Renal Physiol; 2022 Aug; 323(2):F156-F170. PubMed ID: 35695380 [TBL] [Abstract][Full Text] [Related]
52. Acquired structural genitourinary abnormalities contributing to deterioration of renal function in older patients with nephropathic cystinosis. Strife CF; Strife JL; Wacksman J Pediatrics; 1991 Dec; 88(6):1238-41. PubMed ID: 1956743 [TBL] [Abstract][Full Text] [Related]
53. Nephropathic cystinosis: an update on genetic conditioning. Topaloglu R Pediatr Nephrol; 2021 Jun; 36(6):1347-1352. PubMed ID: 32564281 [TBL] [Abstract][Full Text] [Related]